

Women and Alzheimer's Disease Risk Begins in Midlife During the Menopausal Transition: Implications for Prevention and Treatment

60th Advisory Committee on Research on Women's Health NIH

Roberta Diaz Brinton, Ph.D.

Center for Innovation in Brain Science

Health Sciences

College of Medicine

University of Arizona

Tucson, AZ

Disclosures

Sponsors

National Institute on Aging
Alzheimer's Drug Discovery Foundation
Alzheimer's Association
Women's Alzheimer's Movement


Patents


- Allopregnanolone a method for enhancing neurological function (US8969329B2)
- Agents, compositions and methods for enhancing neurological function (US20170258810A1)
- Agents, compositions and methods for treating and preventing Alzheimer's disease (PCT WO2019/178230)
- Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms (US8680140B2).
- Phytoestrogenic formulations for alleviation or prevention of neurodegenerative diseases (US8552057B2)
- Neuroprotection and myelin repair using nestorone® (US9446051B2)

BioTech


NeuTherapeutics, LLC.

Perimenopause-Menopause Transition of Female Brain is a Mid-Life Neurological Transition







Early Midlife Bioenergetic Transition in Female Brain: Implications for Risk of Alzheimer's in Later Life




Early Midlife Bioenergetic Transition in Female Brain: Implications for Risk of Alzheimer's in Later Life



Early Midlife Bioenergetic Transition in Female Brain: Implications for Risk of Alzheimer's in Later Life



Metabolic Reprogramming Transitions in Mid-Life Female Brain




Brinton et al., Nature Rev Endo (2015); Mishra, A. et al. iScience 23(12), (2020); Wang, Y. et al., Sci Rep 10, 8528 2020; Ding et al., PLoS One, 2012; Yin et al., Neurobio Aging 2015; Klosniski et., al., EBioMedicine 2015; Mishra, A. et al., Front Aging Neurosci 2018; Yao J et al., Proc Natl Acad Sci USA. 2009 Aug 25;106(34)

What is the source of ketone bodies to fuel a starving brain?




The Brain is the Most Lipidated Organ of the Body: 60% of Brain Matter is White Matter



Surface of the left hemisphere with 50,000 tracts visualized. Colors indicate fiber direction (red = left-right; blue = superior-inferior; green = anterior-posterior (Raikes & Brinton, 2021)




Coordinated Systems of Biology Between Immune and Metabolic Systems to Sustain Neuronal Survival Through Utilization of White Matter Lipids






Metabolic Reprogramming of Brain: Coordinated Metabolic and Immune System Activation





Neuro-Immune and Metabolic Reprogramming Transitions in Mid-Life Female Brain




Brinton et al., Nature Rev Endo (2015); Mishra, A. et al. iScience 23(12), (2020); Wang, Y. et al., Sci Rep 10, 8528 2020; Ding et al., PLoS One, 2012; Yin et al., Neurobio Aging 2015; Klosniski et., al., EBioMedicine 2015; Mishra, A. et al., Front Aging Neurosci 2018; Yao J et al., Proc Natl Acad Sci USA. 2009 Aug 25;106(34)

Utilization of White Matter Lipids: Link to Menopausal Hot Flashes





Precision Menopausal Hormone Therapy: Timing Matters Estrogen Sustains Brain Health Does Not Reverse Disease





Brinton et al., Nature Rev Endo (2015); Mishra, A. et al. iScience 23(12), (2020); Wang, Y. et al., Sci Rep 10, 8528 2020; Ding et al., PLoS One, 2012; Yin et al., Neurobio Aging 2015; Klosniski et., al., EBioMedicine 2015; Mishra, A. et al., Front Aging Neurosci 2018; Yao J et al., Proc Natl Acad Sci USA. 2009 Aug 25;106(34)

Is There Evidence for Metabolic Reprogramming in the Human Brain?



Discovery to Clinical Translation: Human Brain Glucose Uptake Declines in Endocrinological Aging







Center for Innovation in

Brain Science

White Matter Loss is Consistent with Myelin Profile of Plasma Metabolome




Metabolomic Auxiliary Fuel Phenotype




Chang et al. Alzheimer's Dement. 2022 Arnold et al.,.Nat Commun. 2020 Mar 2;11(1):1148.


Decline in Brain Glucose Metabolism is Coincident with Decline in White Matter Volume and Emergence of Beta Amyloid Plaque During Menopausal Transition



18F-fluoro-2deoxyglucose
(FDG)—PET brain
glucose metabolism
as a function of
chronologic vs
endocrine aging

PiB—PET β-amyloid deposition as a function of chronologic vs endocrine aging







If Loss of Estrogen Initiates MidLife Trajectory of Vulnerability,

Does Menopausal Hormone Therapy Impact Risk of Alzheimer's?



Menopausal Hormone Therapy (MHT) and Neurodegenerative Diseases (NDD): A Retrospective Analysis in 379,352 Women





Kim, YU.. Brinton RD Alzheimers Dementia 2021 May 13;7(1)



If Estrogen is Beneficial for the Brain......

Why do 80% of women elect not receive hormone therapy for menopausal symptoms?

Fear of Breast Cancer

To sustain brain health, had to address breast health


Distribution of Estrogen Receptor α & β in Brain: ER β Estrogenic Mechanisms

$\mathsf{ER}\alpha$ Distribution in Brain Dentate gyrus CA3 Cortex Thalamus


Amygdala

CA3

$\mathsf{ER}\beta$ Distribution in Brain




$\mathsf{ER}\beta$ Mechanism of Action in Brain



Estrogen Receptor β Inhibits Breast Cancer Cell Proliferation and Migration

- Estrogen receptor β inhibits 17β-estradiol-stimulated proliferation of the breast cancer cell line T47D, PNAS, 2004, Jan 26, 2004, 101 (6) 1566-1571
- Estrogen receptor β inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004 Jan 1;64(1):423-8.
- Estrogen receptor β inhibits breast cancer cells migration and invasion through CLDN6-mediated autophagy, J Exp Clin Cancer Res 2019 Aug 14;38(1):354.
- Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer. *Nature* Breast Cancer, (2022) 8:20

Estrogen Receptor β Targeted PhytoSERMs for Menopausal Symptoms: Phase 1b/2a Clinical Trial for Safety and Feasibility



NIA 5R01AG033288

Clinicaltrials.gov NCT01723917

PHASE 1b/2a: RCT

PARTICIPANTS

- 70 Peri-Post Menopausal Women
- Vasomotor Symptoms
- Subjective Cognitive Complaint

TREATMENT

- Placebo
- 50 mg
- 100 mg

1/day for 3 months

PRIMARY OUTCOMES

- Safety
- Pharmacokinetics

EXPLORATORY OUTCOMES

- Hot Flash
- Cognitive Function

PRIMARY OUTCOMES

- ✓ No indicators of toxicity
- ✓ Predictive pharmacokinetics
- ✓ Effective dose: 50 mg/daily
- ✓ Detection of change in hot flash frequency feasible
- ✓ Biomarker of responder feasible

Hernandez et al., Menopause, 2018, 2:191-196 Schneider et al., Menopause: 2019, 26, No. 8, pp. 874-884

PhytoSERM Development: Pharmaceutical Rigor for PhytoSERM Nutraceutical

Preclinical Development

Phase I Safety and Feasibility
Clinical Trial

Safety and Chronic Toxicity Profile

Phase 2 Proof of Concept Clinical Trial

Established: Established: Established: Established: Established:

NIA R01AG075122 / NCT05664477

PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial



NIA R44AG07802 / NCT06186531

PhytoSERM for Menopausal Hot Flashes and Sustained Brain Health https://www.hfrelief.org/

Key Concepts

- Menopause is a Neurological Transition that can unmask vulnerability to age-associated neurodegenerative disease.
- Menopausal Transition involves both the Metabolic and Immune Systems of the Brain
- Menopausal Hormone Therapy <u>Sustains and Promotes</u> Healthy Brain Aging –

Does Not Reverse Disease

• Promoting Brain and Breast Health is Feasible through ER β selective formulation

Gaps and Opportunities in Women's Brain Health

- Precision Hormone Therapy to Prevent Neurological Risks
- Biomarkers of Transition Stage beyond Clinical Symptoms that Determine Reflect Neurological Health or Vulnerability


Brinton Research Team, Sponsors & Collaborators

TEAM

- Tian Wang, Ph.D.
- Gerson Hernandez, M.D.
- Claudia Lopez
- Jennifer Mao
- Adams Raikes, Ph.D.
- James Stanton
- Jean Paul Wiegand, Ph.D.
- Raymond Sheng, Ph.D.
- Gregory Branigan, M.D. Ph.D.
- Pavel Rychetsky, Ph.D.
- Avnish Bhattrai
- Helena Cortes, PharmD
- Nicole Delatorre
- Melissa Garza
- John McLean
- Georgina Torrandell, PharmD
- Hannah Van Rossum

SPONSORS

- National Institute on Aging
- Alzheimer's Drug Discovery Fd
- Alzheimer's Association
- Womens Alzheimer's Movement
- Robins Trust



National Institute on Aging

- P01AG026572
- R01AG057931
- RF1AG059093
- R37AG053589
- R01 AG063826
- R43 AG063674
- 5R25NS107185
- T32AG061897

COLLABORATORS

- Fei Yin, Ph.D. University of Arizona
- Lisa Mosconi, Ph.D. Cornell University
- Francesca Vitali, Ph.D. University of Arizona
- Kathleen Rodgers University of Arizona
- Lon Schneider, M.D. USC NIA ADRC
- Dawn Matthews, Ph.D. ADMdx
- Eric Reiman, M.D. Banner AD Institute, AZ ADRC
- Helena Chui, M.D. USC NIA ADRC
- Rui Chang, Ph.D., University of Arizona
- Julie Zissimopoulos, Ph.D., USC
- Meng Law, M.D. USC NIA ADRC
- Yonggang Shi, Ph.D. USC LONI
- Rima Kaddurah-Daouk, Ph.D, Duke University
- Matthias Arnold, Ph.D., Helmholtz Munich
- Eugenia Trushina, Ph.D., Mayo Clinic Rochester
- Nophar Geifman, Ph.D. Univ Manchester
- Regine Sitruk-Ware, M.D. Rockefeller Population Counc



Detecting Cognitive Resilience vs Vulnerability in Healthy Women



